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1. Preamble
1.1. Need for developing case definitions and guidelines for viscerotropic disease as an
adverse event following immunization
Viscerotropic disease (VTD) is defined as acute multiple organ system dysfunction that
occurs following vaccination. The severity of VTD ranges from relatively mild multisystem
disease to severe multiple organ system failure and death. The term VTD was first used
shortly after the initial published reports in 2001 of febrile multiple organ system failure
following yellow fever (YF) vaccination [1–7]. To date, VTD has been reported only in
association with YF vaccine and has been thus referred to as YF vaccine-associated
viscerotropic disease (YEL-AVD).
YF vaccine is manufactured from the live attenuated 17D virus substrain. It is considered
relatively safe and effective in preventing YF disease, which results from YF virus
transmission through the bite of an infected mosquito [8]. YF virus circulates in sub-Saharan
Africa and tropical South America, where it causes endemic and intermittently epidemic
disease. Most YF disease in these areas is attributable to jungle (sylvatic) or savanna
(intermediate) transmission cycles, which occur predominantly in sparsely populated
forested areas and rural villages, respectively [8]. To protect vulnerable populations,
endemic countries target YF vaccination efforts towards their residents, who reside in both
rural and urban settings with varying resources.
YEL-AVD is believed to result from widespread dissemination and replication of live
attenuated 17D YF vaccine virus, similar to the natural YF virus. Virologic studies have
documented vaccine virus in a number of postmortem tissues obtained from YEL-AVD case
patients [1–3,9–14]. The initial symptoms of YEL-AVD are nonspecific, including fever,
headache, malaise, myalgia, arthralgia, nausea, vomiting, and diarrhea, and resemble those
of the early phase of YF disease. As YEL-AVD progresses, jaundice can appear, along with
thrombocytopenia and elevations of hepatic transaminases, total bilirubin, and creatinine.
Severe YEL-AVD is characterized by hypotension, hemorrhage, acute renal failure, and
acute respiratory failure. Less frequent manifestations include rhabdomyolysis and
disseminated intravascular coagulation (DIC). There is no specific therapy for YEL-AVD;
treatment is supportive. YEL-AVD is fatal in more than 60% of reported cases [8], although
this rate is probably an overestimate because case confirmation is more likely in fatal cases
than nonfatal ones.
As of March 2010, the Brighton Collaboration Viscerotropic Disease Working Group had
identified 60 published and unpublished reports of YEL-AVD from Asia, Australia, Europe,
and North and South America. A number of suspected YEL-AVD cases have been detected
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in Africa through enhanced surveillance conducted in conjunction with mass YF vaccination
campaigns, but information on these cases is limited. YEL-AVD cases have been reported
following vaccination with different attenuated 17D YF vaccine virus substrains that have
been produced by several manufacturers [8]. YEL-AVD appears to occur only after a
person’s first YF vaccination; there are no reports of YEL-AVD following booster doses of
YF vaccine. The median time from vaccination until symptom onset is 3 days (range: 1–8
days). The median time from YF vaccination until death is 10 days (range: 7–30 days) [8].
Data from US and European travelers indicate that YEL-AVD occurs at a frequency of 0.3–
0.4 per 100,000 YF vaccine doses distributed [15–17]. An analysis of fatal cases in mass
vaccination campaigns in Brazil yielded a lower risk estimate of 0.0043–0.2131 per 100,000
doses administered [9]. However, more recent risk estimates reported from Brazil, using
data from vaccination campaigns in 2008–2009, are similar to those reported from the
United States and Europe [18]. In 2007, an unprecedented cluster of five cases of YEL-
AVD, four of which were fatal, occurred following the use of a single lot of YF vaccine
administered as part of a vaccination campaign in a nonendemic area of Peru. The overall
incidence of YEL-AVD in this campaign was 7.9 per 100,000 doses administered, and the
lot-specific incidence was 11.7 per 100,000 doses [12]. A thorough investigation found no
clear explanation for the substantially higher incidence of YEL-AVD in this campaign or
with this specific vaccine lot.
Advanced age has been identified as a risk factor for YEL-AVD. Two analyses of YEL-
AVD reports to the Vaccine Adverse Events Reporting System (VAERS) in the United
States yielded a reporting rate of 1.4–1.8 cases of YEL-AVD per 100,000 doses for persons
aged ≥60 years [15,16]. This rate is several times higher than the overall reporting rate of
0.3–0.4 per 100,000 doses. In addition, a history of thymus disease or thymectomy is
considered a risk factor, based on the observation that four of the first 23 reported cases of
YEL-AVD had a history of thymectomy for either benign or malignant thymoma [19].
In 2002, an informal Yellow Fever Vaccine Safety Working Group (YFWG) was convened
to discuss cases of YEL-AVD. The YFWG included staff of the US Centers for Disease
Control and Prevention (CDC), World Health Organization (WHO), various US academic
institutions, the US Food and Drug Administration, the US Department of Defense, and
vaccine manufacturers. This working group reviewed reports to VAERS of serious adverse
events following YF vaccination and developed a case definition for YEL-AVD. This case
definition, published in original [8] and in modified form [20], provided the basis for case
definitions subsequently used in the investigation of suspected YEL-AVD cases in Brazil
and Peru [12], by a major YF vaccine manufacturer, and by WHO [21,22]. However, this
case definition was never subjected to a formal peer review process and was never adopted
as an international standard.
The original YFWG case definition has limitations. It combines case-finding criteria, useful
to search surveillance systems for reports of potential cases of YEL-AVD, with clinical and
laboratory abnormalities used for case confirmation. To be classified as YEL-AVD, a case
must meet the case-finding criteria (fever and at least one other symptom from a list of
nonspecific symptoms) and have at least one of eleven listed clinicopathologic
manifestations that indicate organ system dysfunction. Given that YEL-AVD is recognized
to be a syndrome of multiple organ system dysfunction (or failure), the case definition
requirement for only one clinical or laboratory abnormality contributes to a lack of
diagnostic specificity. The original YEL-AVD case definition includes a YF vaccine
causality assessment, without explanation of the rationale for the selected causality criteria.
Moreover, the case definition and causality assessment are linked together without provision
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for broader application of the YEL-AVD case definition to similar reactions that might
occur with other vaccines.
Since 2007, the Yellow Fever Initiative (YFI), a collaboration of WHO and UNICEF, has
assisted countries in West Africa to plan and conduct mass vaccination campaigns against
YF. During 2007 through 2010, the YFI program vaccinated 57 million people in 10
countries [23]. In addition, the YFI has assisted 22 African countries in the successful
introduction of YF vaccine into their routine childhood immunization programs and has
been involved in expanding routine childhood YF vaccination coverage in the Americas.
The YFI plan for these mass vaccination campaigns includes protocols for investigating
adverse events following immunization (AEFI) [21,22]. However, the lack of a globally
accepted case definition for YEL-AVD, which would be applicable to resource-poor
settings, was identified as an impediment to accurate and standardized AEFI case
classification. Consequently, the WHO recommended to the Brighton Collaboration
(https://brightoncollaboration.org/public) leadership that a Brighton Collaboration working
group be formed to develop a standard case definition for VTD.
To this end, the Brighton Collaboration initiated a working group in 2008 to develop a
standardized case definition and guidelines for the collection, analysis, and presentation of
data for VTD as an AEFI. The case definition and guidelines are intended to be applicable in
diverse geographic, administrative, and cultural regions, regardless of differences in the
availability of resources, including laboratory diagnostic capabilities, and access to health
care. Standardized application of this definition with its guidelines will enable data
comparability and hopefully lead to a better understanding of VTD. Previously published
WHO guidance regarding the case definition and data collection for YEL-AVD, as well as
the case definition developed by the YFWG, preceded the development of these guidelines
[8,20–22]. The more recent and more detailed Brighton Collaboration case definition and
guidelines presented here are preferred.
1.2. Methods for the development of the case definition and guidelines for VTD as an AEFI
Following the process described in the Brighton Collaboration overview paper [24], the
Brighton Collaboration VTD WG (the WG) comprised 30 members from 10 countries,
representing academia, public health, regulatory organizations, and industry. The results of
the web-based survey of the VTD case definition, completed by the reference group, with
subsequent discussions in the working group, can be viewed at:
https://brightoncollaboration.org/public/resources/surveyfeedback/VTDcasedefinition.html.
To guide development of the case definition and guidelines, a systematic literature search
identified articles addressing YEL-AVD. Because no specific indexing term for this serious
AEFI existed at the time of the literature search, a combination of more general search terms
was used, including yellow fever vaccine, immunization, viscerotropic, multiple organ
failure, systemic inflammatory response syndrome, disseminated intravascular coagulation,
sepsis, liver dysfunction, kidney dysfunction, and adverse event. Sources included the
Cochrane Library, MEDLINE (1950-July week 3, 2008) and Embase (1980-week 30, 2008).
Nine hundred articles were initially identified. Based on a review of the title and abstract, 21
articles (20 in English and 1 in Chinese) were selected for further evaluation. These
publications were mainly case reports of one or more cases of YEL-AVD. Several were
reports of molecular analyses of YF vaccine strain virus isolates from patients who had
developed YEL-AVD and included limited clinical case report information. Although
several of the publications referred to using the YFWG case definition for YEL-AVD, none
listed the details of the case definition. Selected published articles and unpublished case
reports available at the CDC and WHO were summarized in an inventory to include
information on the clinical signs and symptoms of 36 cases of YEL-AVD. The WG
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reviewed this inventory and designated case definition criteria based on the most frequently
reported clinicopathologic manifestations.
An additional literature search of MEDLINE was performed by the WG, specifically to
identify reports of multiple organ system disease following immunization with other
vaccines. Search terms used were multiple organ failure and vaccines; multiple organ failure
and measles mumps rubella or varicella or herpes zoster or polio or rotavirus or influenza or
Bacille Calmette-Guérin (BCG) or Ty21a typhoid vaccine. Published reports of multiple
organ system failure were identified following administration of varicella vaccine (2
reports), oral polio vaccine (1 report), and BCG vaccine (numerous reports). The majority of
articles retrieved from the multiple organ failure AND BCG search were reports of multiple
organ system failure and sepsis following intravesical administration of BCG used to treat
bladder cancer in adults. However, there were a few reports of disseminated BCG infection
in infants after BCG immunization. These reports were retrieved and reviewed.
Additionally, the 900 abstracts from the original literature search were re-reviewed for any
reports of multiple organ system failure associated with vaccines other than YF vaccine. No
such reports were identified by this last strategy.
1.3. Rationale for selected decisions about the case definition for VTD as an AEFI
1.3.1. The term viscerotropic disease—The WG chose to use the term “viscerotropic
disease,” rather than “multiple organ system failure” because it is the term currently used in
the vaccine safety literature to describe this AEFI, and we felt it more accurately describes
both the pathogenesis and the full spectrum of disease severity. The WG defined
“viscerotropic disease” rather than “yellow fever vaccine-associated viscerotropic disease”
because we consider it important to first confirm the clinical entity itself at a given level of
diagnostic certainty and afterward to assess its causal relation to vaccination in a separate
step using a causality algorithm. Although the term VTD has thus far been applied only to
the syndrome of multiple organ system failure following YF vaccination, other cases of
multiple organ system failure associated with varicella [25,26], poliovirus [27], and BCG
[28] vaccines were found through the literature search. These AEFIs were not entirely
similar to those seen with YF vaccine (e.g., different age groups or time course). However,
overlapping clinical features suggest that the VTD case definition would have utility for
multiple vaccines. Additionally, having a stand-alone VTD case definition exclusive of any
assessment for YF vaccine causality will allow for its potential future use following
immunization with other, not yet licensed vaccines. An example of the latter is the live
chimeric vaccines in development that are based on the 17D YF vaccine virus backbone.
Although clinical trials to date have shown these vaccines to have excellent safety profiles
[29], the possibility cannot be eliminated that future, post-licensing experience might
demonstrate the rare occurrence of VTD.
1.3.2. Structure of the VTD case definition—The Brighton Collaboration VTD case
definition has been constructed in accordance with the general format for Brighton
Collaboration case definitions, with three levels of diagnostic certainty. Level 1 has the
highest degree of specificity and the lowest degree of sensitivity. Moving from Level 1 to
Level 3 there is a stepwise increase of sensitivity with a corresponding decrease in
specificity. The case definition levels differ in diagnostic certainty, not in clinical severity of
VTD. Similarly, levels of diagnostic certainty do not reflect causal association with a given
vaccine.
The WG designated major and minor criteria for each clinicopathologic manifestation of
VTD, to be used in various combinations to meet the requirements of each level of the case
definition. The distinction between corresponding major and minor criteria is based on
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diagnostic certainty, not on clinical severity, a relationship which is consistent with that
between the three levels of the case definition. The major and minor criteria for each
clinicopathologic manifestation were particularly selected to facilitate application of the case
definition in diverse clinical settings with varying diagnostic resources. For example,
elevated serum total bilirubin indicates liver dysfunction to a higher degree of diagnostic
certainty than jaundice, which is observer-dependent and may have causes other than liver
dysfunction. Consequently, elevation of total bilirubin is a major criterion and jaundice is a
minor criterion for the clinicopathologic manifestation of liver dysfunction.
The WG recognized that categorizing individual clinical and laboratory abnormalities as
discrete case definition criteria is an artificial construct. VTD involves multiple organ
systems and physiologic processes that are dynamically interconnected in the body’s normal
functioning, as well as in pathophysiologic states. Abnormal laboratory results primarily
identified with one system might actually result from the dysfunction of several organ
systems. Nevertheless, the ability to easily apply the case definition to a complex clinical
event requires that the clinicopathologic abnormalities comprising the case definition be
categorized discretely.
The WG decided to exclude any symptoms from its VTD case definition because symptoms
are too general and nonspecific to differentiate the multiple organ system syndrome of VTD
from other clinical events. Although symptoms might be useful for case finding, they do not
contribute substantially to any degree of diagnostic certainty about VTD. Fever deserves
special mention because it is both a symptom and a physical sign. Fever as a symptom was
excluded for the aforementioned reasons; fever as a sign was excluded from the case
definition because, although it is objectively measured, it is not a specific indicator of organ
dysfunction.
1.3.3. Decisions about specific major and minor criteria—Because the previous
YFWG case definition for YEL-AVD [8] has been widely used in the assessment of VTD,
this WG deliberated in great detail any changes made. For example, although tachycardia
and bradycardia are both included in the previous case definition of YEL-AVD, the WG
decided to exclude these from the Brighton Collaboration VTD case definition. The WG felt
that while tachycardia might be generally indicative of severe illness, it is too nonspecific a
clinical sign to add diagnostic certainty. Faget’s sign, which is characteristic of YF, is a
bradycardia relative to the expected heart rate increase accompanying elevated body
temperature [30]. However, it does not appear to be a common feature of YEL-AVD, as it
was noted in only one of 31 cases in which symptoms were reported.
The previous YFWG case definition of YEL-AVD defines thrombocytopenia as platelet
count less than 100,000/mm3, as does the case definition of thrombocytopenia as an adverse
drug reaction developed by an expert group convened by the Council for International
Organizations of Medical Sciences (CIOMS) [31]. This WG chose the same threshold, since
65% of YEL-AVD cases in the inventory had a platelet count below this level; it
unequivocally reflects an abnormally low platelet count. The WG chose to use the term
“platelet disorder” rather than “thrombocytopenia” to label the major criterion of a low
platelet count, to avoid confusion with the existing Brighton Collaboration general case
definition of thrombocytopenia, defined as a platelet count less than 150,000/mm3 [32].
Rhabdomyolysis is a less common manifestation of YEL-AVD that has been reported with
severe cases. The previous YFWG case definition of YEL-AVD defines rhabdomyolysis as
a measured serum creatine phosphokinase (CPK) level of greater than five times normal.
Published articles on rhabdomyolysis indicate that an elevation of CPK is the most sensitive
indicator of rhabdomyolysis [33,34]. Although there is no established diagnostic cut-off
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level of CPK for the diagnosis of rhabdomyolysis, five times the upper limit of normal is
commonly used in clinical practice [33–35]. The consensus of the WG was to use the
commonly applied threshold of CPK elevation for the major criterion of rhabdomyolysis.
The WG chose as the corresponding minor criterion for rhabdomyolysis a positive urine
dipstick test for blood with a negative urine microscopic examination for red blood cells
(RBCs). If no RBCs are detected by urine microscopy, a positive dipstick test for blood can
usually be attributed to myoglobinuria [36–38]. This is the only minor criterion selected for
the VTD case definition that involves laboratory testing, but the required laboratory
equipment is basic and should be available in many clinics in resource-poor settings.
Although myoglobinuria has been described to impart a tea or cola color to urine,
bilirubinuria can produce a similar color [39]. Since bilirubinemia is reported more
commonly than rhabdomyolysis in cases of YEL-AVD, bilirubinuria likely occurs more
frequently than myoglobinuria. Hence, urine discoloration is too nonspecific to be used as
the minor criterion for rhabdomyolysis.
Disseminated intravascular coagulation (DIC) also has been reported with severe cases of
YEL-AVD. However, abnormalities of a single laboratory coagulation test were reported
more frequently in the inventory of YEL-AVD case reports than DIC or elevated fibrin
degradation products (FDP). The WG recognized that coagulopathy may manifest on a
spectrum ranging from mild elevation of the international normalized ratio (INR),
prothrombin time (PT), or activated partial thromboplastin time (APTT), to the detection of
FDP and presence of hemorrhage suggestive of DIC. Consequently, using the broader
category of coagulopathy rather than DIC as a major criterion adds sensitivity to the VTD
case definition. In clinical practice, DIC is not defined by any one laboratory test, but rather
is a clinical diagnosis based on abnormalities of multiple laboratory tests of coagulation,
including FDP and platelets, along with clinical signs. The WG decided to include
laboratory evidence of coagulopathy or clinically evident hemorrhage from more than one
body site as elements of the major coagulopathy criterion; the latter was felt to be more
consistent with DIC than hemorrhage from a single body site. The corresponding minor
criterion was designated as clinically evident hemorrhage from one body site.
The WG excluded hematuria as one of the criteria for coagulopathy because it is prevalent to
a significant degree in the general population, especially in Africa. Studies in localized
populations of several West African countries have demonstrated an overall prevalence of
Schistosoma haematobium infection in the range of 55%–65% [40,41]. Among these
infected persons, microhematuria prevalence ranged from 36% to 76%, depending on age
and intensity of infection. The prevalence of microhematuria in uninfected individuals was
17% in one study in Africa [40]. This finding is consistent with studies in other settings that
have reported a micro-hematuria prevalence of up to 30% in apparently healthy people
[42,43]. Furthermore, approximately one in three persons in West Africa carry the sickle cell
trait, for which the most frequent complication is hematuria, both microscopic and
macroscopic [44]. Given the relatively high background prevalence of hematuria from
various causes, hematuria is too nonspecific to be used as an indicator of coagulopathy for
the VTD case definition.
1.3.4. Timing post-immunization—Because the case definition defines a clinical entity
without inference of a causal relation to a given vaccine exposure, the time interval between
immunization and onset of the VTD cannot be part of the definition. Generally, the WG
recommends surveillance for signs of VTD for 30 days following vaccination. This time
period will facilitate detection of VTD cases in resource-poor settings in which a case might
be suspected and reported only after a patient’s death. For YEL-AVD, the reported time
interval between vaccination and symptom onset has been 1–8 days [8]. One reported case
involved an unclear time to symptom onset following YF vaccination, with the most
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conservative interpretation of the available clinical information being 18 days [12]. The
evidence suggests that this patient was immunosuppressed prior to vaccination or developed
immunosuppression as a result of medication prescribed for initial symptoms following
vaccination. The time interval between vaccination and death for reports of YEL-AVD is 7–
30 days [2,12]. The recommended 30-day surveillance period for VTD allows for potential
variation in time interval to symptom onset that might occur in the future in association with
other live or chimeric vaccines. Finally, 30 days is commonly used as a surveillance period
for collecting reports of adverse events following vaccination.
1.3.5. YF vaccine causality—The case definition itself is independent from any
assessment of causality. However, because of the clear association of VTD with YF vaccine,
the WG decided to create a separate, unlinked algorithm for YF vaccine causality, to be
included with this case definition and guidelines (see Appendix A). A causality assessment
previously had been part of the YFWG case definition. Unlinking the revised causality
algorithm from the VTD case definition will allow the Brighton Collaboration VTD case
definition to be applicable to any vaccine. In addition, the causality assessment will help
differentiate VTD caused by the vaccine from disease manifestations of wild type YF in the
setting of vaccination campaigns undertaken in areas where wild type YF is endemic and/or
epidemic.
1.3.6. Standardizing the use of the case definition—Recognizing the many
variables and uncertainties affecting both the definition and the diagnosis of VTD, the WG
has attempted to establish useful and practical guidelines for standardizing the collection,
analysis, and presentation of data on VTD in the setting of pre- and post-licensure clinical
trials, surveillance, and retrospective epidemiologic studies of vaccine safety. The guidelines
are not intended to establish criteria for management of ill patients. As they represent a
minimum standard, additional data may be collected, analyzed, and presented as deemed
necessary by the investigators. This flexibility is particularly relevant for surveillance of
VTD as a potential AEFI with new vaccines against chronic diseases (e.g., diabetes mellitus,
rheumatoid arthritis) and therapeutic vaccines (e.g., tumor vaccines), as well as genetically
engineered vaccines, mucosal vaccines, or vaccines with slow-release delivery systems,
which may require different standards.
Similar to all Brighton Collaboration case definitions and guidelines, regular review of the
definition with its guidelines is planned (every 3–5 years) or more often, if needed. The WG
encourages users of the case definition to provide feedback on its applicability to the
Brighton Collaboration at https://brightoncollaboration.org/public/contact.html.
2. Case definition of viscerotropic diseasea,b
Level 1 of diagnostic certainty
• ≥3 major criteriac
Level 2 of diagnostic certainty
• 2 major criteriac
OR
• 1 major criterion and ≥2 minor criteriac
Level 3 of diagnostic certainty
• ≥3 minor criteria
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• 1 major criterion and 1 minor criterionc
a
The case definition should be applied when there is temporal association (see Section 1.3.4) with vaccination and no clear
alternative diagnosis to account for the symptoms.
b
Previously published WHO guidance (Refs. [21,22]) regarding the case definition and data collection for YEL-AVD
preceded the development of these guidelines; the more recent and more detailed Brighton Collaboration case definition
and guidelines presented here are preferred.
c
Whenever ≥1major criteria or both a major and minor criteria are used to meet the case definition, they must each
represent different organ systems (e.g., hepatic versus renal).
2.1. Major and minor criteria used in the case definition of viscerotropic disease
Major criteria
Hepatic: Total bilirubin ≥ 1.5X ULNd
[≥1.5X patient’s baseline value if known]
OR
ALT or AST ≥ 3X ULNd
[≥3X patient’s baseline value if known]
Renal: Creatinine ≥1.5X ULNd
[≥1.5X patient’s baseline value if known]
Musculoskeletal: CPK ≥5X ULNd
Respiratory: Oxygen saturation ≤ 88% on room air
OR
Requirement for mechanical ventilation
Platelet disorder: Platelets < 100,000/μL
Hypotension: Requirement for vasopressor drugs to maintain systolic BP
Coagulopathy: INR ≥1.5 OR Prothrombin time ≥1.5X ULNd OR Activated partial thromboplastin time ≥1.5X
ULNd OR elevated FDPe OR hemorrhage from more than one sitef
d
ULN = upper limit of normal for the reference range of normal values reported by the clinical laboratory performing the
indicated test.
e
FDP = Fibrin degradation products.
f




Renal: Urine output <500 mL urine/24 h for adults
Urine output <0.5 mL/kg/h for childreng
Musculoskeletal: Positive urine dipstick test for blood with a negative urine microscopy exam for red blood cells
Respiratory: Increased respiratory rate for ageh
Platelet disorder: Petechiae or purpura present
Hypotension: Systolic BP <90 mmHg for adults
Systolic BP <5th percentile for age in children <16 years






 Metrorrhagia or menorrhagia
 Gingival hemorrhage
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 Persistent bleeding from needle puncture sites
g
Applies to children <13 years of age.
h
Age-specific thresholds for increased respiratory rate (breaths/min).
6–11months: >50.
1–5 years: >40.
6 years and older >20.
(Modified from: World Health Organization. The management of acute respiratory infections in children: practical
guidelines for outpatient care. 1995. Available at: http://whqlibdoc.who.int/publications/1995/9241544775eng.pdf).
3. Complementary guidelines for data collection, analysis, and presentation
of viscerotropic disease
It was the consensus of the Brighton Collaboration VTD WG to recommend the following
guidelines to facilitate meaningful and standardized collection, analysis, and presentation of
information about VTD. However, implementation of all guidelines might not be possible in
all settings. The availability of information may vary, depending upon resources and
geographic region and whether the source of information is a prospective clinical trial, post-
marketing surveillance, an epidemiologic study, or an individual case report of VTD. Also,
as explained in more detail in the Brighton Collaboration overview paper [24], these
guidelines have been developed by this WG for guidance only and are not to be considered a
mandatory requirement for data collection, analysis, or presentation.
3.1. Data collection
These guidelines provide a desirable standard for collection of data on VTD to allow for
comparability of data, and are recommended as a supplement to other data that might be
collected for any specific study question and investigation setting. The guidelines are not
intended to guide the primary reporting of VTD to a surveillance system or study monitor.
Investigators developing a data collection tool based on these data collection guidelines also
need to refer to the criteria in the case definition, which are not repeated in these guidelines.
Guidelines 2, 4, 5, 11–13, 18–25 below have been developed to address data elements for
the collection of adverse event information, as specified in general drug safety guidelines by
the International Conference on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use [45] and the form for reporting of drug adverse events by
the CIOMS [46]. These data elements include an identifiable reporter and patient, one or
more prior immunizations, and a detailed description of the AEFI, in this case, of VTD. The
additional guidelines have been developed as guidance for the collection of supplemental
information to allow for a more comprehensive understanding of VTD as an AEFI.
3.1.1. Source of information/reporter—For all cases and/or all study participants, as
appropriate, the following information should be recorded:
1) Date of report.
2) Name and contact information of person reporting4 VTD, in accordance with
country-specific data protection law.
4 If the reporting center is different from the vaccinating center, appropriate and timely communication of the adverse event should
occur.
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3) Relationship of the reporter to the vaccine recipient (e.g., immunizer [clinician,
nurse], attending physician, family member [indicate relationship], self [vaccine
recipient], other).
3.1.2. Vacinee/control—For all cases and/or all study participants, as appropriate, the
following information should be recorded:
3.1.2.1. Demographics
4) Case/study participant identifiers (first name initial followed by last name
initial) or code (or as otherwise specified in country-specific data protection
laws).
5) Date of birth, age, sex.
6) Country of residence.
7) Occupation(s).
8) For infants (≤12 months of age): gestational age at birth and birth weight.
3.1.2.2. Clinical and immunization history
9) Medical history prior to most recent immunization(s), including hospitalizations,
surgeries (e.g., thymectomy), underlying diseases/disorders, pre-immunization
signs and symptoms.
10) Any medication history prior to, during, and after vaccination, including
prescription and nonprescription medication (e.g., herbal or homeopathic
medication). These medications should be distinct from those used to treat VTD
(refer to Guideline 23). The medication history prior to vaccination should
include all medications used in the week prior to vaccination, except for
medications with long half-life or long-term effect (e.g., immunoglobulins,
blood products, immunosuppressants, and immunomodulators), in which case
any use several months prior to vaccination should be recorded. (References on
pharmacokinetics for individual medications should be consulted to determine
the appropriate length of this time interval).
11) Immunization history (i.e., previous immunizations received more than 30 days
before VTD symptom onset, especially vaccines known to cause VTD, such as
YF vaccine, and any AEFI ever experienced).
3.1.3. Details of the immunization—For all cases and/or all study participants, as
appropriate, the following information should be recorded:
12) Date, time, and geographic location of administration (e.g., city or town, state or
province, and country) of all immunization(s) given within 30 days prior to
onset of VTD symptoms.
13) Description of all vaccine(s) given within 30 days prior to onset of VTD
symptoms (name of vaccine, manufacturer, lot number, expiration date, multi-
or mono-dose vial, volume [e.g., 0.25 mL, 0.5 mL, etc.], dose number if part of
a series of immunizations against the same disease(s), and the manufacturer, lot
number, and expiration date of any diluent used).
14) Anatomical sites (including left or right side) of all immunizations (e.g., vaccine
A in proximal left lateral thigh, vaccine B in left deltoid).
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15) Route and method of administration (e.g., intramuscular, intradermal,
subcutaneous, oral, intranasal, needle-free [including type and size] or other
injection devices).
16) Context of immunization (e.g., routine childhood immunization program,
preventive mass immunization campaign, mass immunization campaign for
outbreak response, routine adult immunization, domestic travel from
nonendemic to endemic area, international travel, occupational risk, military
requirements).
3.1.4. The adverse event—For all cases at any level of diagnostic certainty and/or all
study participants, as appropriate, the following information should be recorded:
17) Criteria fulfilled to meet the case definition and other signs or symptoms
indicative of VTD.
18) Detailed clinical description of signs and symptoms of VTD (in particular
jaundice, hypoxia, hypotension, oliguria, tachypnea, petechiae or purpura, or
hemorrhage).
19) Date and time of onset,5 first observation,6 diagnosis,7 end of an episode,8 and
last observation.9
20) Concurrent signs, symptoms, and diseases other than the event described.
21) Values and units of routinely measured parameters (cm, °C, etc.)–in particular
those indicating the severity of VTD. Normal ranges used in the particular
laboratory or clinic setting should be reported for each parameter measured. The
date of specimen collection and/or measurement for each parameter should also
be recorded.
22) Results of laboratory examinations, other clinical tests, surgical and/or
pathological findings and diagnoses. If possible, attempts should be made to
have laboratory testing performed at reliable and accredited laboratories. If more
than one measurement of a particular parameter is taken and recorded, the value
corresponding to the largest deviation from the expected normal value or range
of that parameter should be reported (e.g., highest serum creatinine, lowest
platelet count).
23) Treatment given for VTD (especially hospitalization, supplemental oxygen,
intravenous fluids, vasopressor drugs, mechanical ventilation, hemodialysis,
steroids, antiviral drugs) and names and addresses of treating physicians and/or
institutions.
24) Detailed description of the outcome at last observation9 of VTD should be
clearly described, such as
• Recovery to pre-immunization health status.
5The date and/or time of onset is defined as the date postimmunization when the first sign or symptom suggestive of VTD occurred.
This may only be possible to determine in retrospect.
6The date and/or time of first observation of the first sign or symptom suggestive of VTD can be used, if date/time of onset is not
known.
7The date of diagnosis of an episode is the date postimmunization the event met the case definition at any level.
8The end of an episode is defined as the date the event no longer meets the case definition.
9VTD not resolved at the end of a predefined follow-up period may be followed up as clinically necessary, and additional reporting
should be encouraged to describe progress until the clinical status is stable. The date of last observation is the date of the last clinical
evaluation of the patient with VTD. “Persistence of event” refers to events continuing to meet the case definition beyond the follow-up
period. “Sequelae” are long-term clinical consequences resulting from VTD.
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• Persistence of the event.
• Sequelae from VTD itself.
• Significant complications of treatment.
• Death; and
• description of any other outcome.
25) Medical confirmation of the event (i.e., patient seen by physician).
26) Presence or absence of concurrent local disease outbreaks or recent travel to an
area affected by a disease outbreak (e.g., yellow fever).
3.1.5. Miscellaneous/general recommendations
27) The duration of surveillance for VTD should be predefined where applicable
(e.g., clinical studies or active follow-up) based on
• Biologic characteristics of the vaccine (e.g., live attenuated versus
inactivated component vaccines).
• Biologic characteristics of the vaccine-targeted disease.
• Biologic characteristics of VTD including patterns identified from
previous reports (e.g., associated with yellow fever vaccine); and
• biologic characteristics of the target population (e.g., nutrition,
underlying disease such as immunodepressing illness).
28) The WG recommends that reports of VTD should be collected at a minimum for
all cases with symptom onset within 30 days following vaccination, based on
previous reports of VTD.
29) Methods of data collection should be consistent within and between study
groups or surveillance systems, if applicable.
30) The frequency and duration of follow-up for VTD, reported during the
surveillance period, should be daily for the first week, weekly for the rest of the
first month, and then monthly for a total of 6 months or until a new status quo is
reached, whichever comes sooner. Follow-up of reported events should attempt
to verify and complete the collection of information as outlined in Section 3.1.
3.2. Data analysis
The following guidelines represent a desirable standard for analysis of data on VTD to allow
for comparability of data and are recommended as a supplement to data analyzed for the
setting and any specific study question(s).
31) Reported events could be classified in one of the following five categories noted
below. Events that meet the case definition should be classified according to the
levels of diagnostic certainty as specified in the case definition. Events that do
not meet the case definition should be classified in one of the additional two
categories for analysis.
Event classification in 5 categories10
Event meets case definition
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1. Level 1: criteria as specified in the case definition for VTD.
2. Level 2: criteria as specified in the case definition for VTD.
3. Level 3: criteria as specified in the case definition for VTD.
Event does not meet case definition11
Additional categories for analysis
4. Reported VTD with insufficient evidence to meet the case definition.12
5. Not a case of VTD.13
32) Events following YF vaccine administration that meet the case definition (Level
1, Level 2, or Level 3 of diagnostic certainty) or are classified as reports of VTD
with insufficient evidence to meet the case definition should be further classified
into one of the following categories, using the YF vaccine causality algorithm in
Appendix A14:
1. Definite yellow fever vaccine-associated causality.
2. Probable yellow fever vaccine-associated causality.
3. Suspect yellow fever vaccine-associated causality.
4. Insufficient data to determine yellow fever vaccine-associated
causality.
33) The interval between immunization and VTD should be specified by using the
date/time of immunization and the date/time of onset5 or first observation6 or
diagnosis7, whichever is most appropriate. The day of immunization is
commonly considered day zero. Whichever numerical designation is used for
the day of immunization should be clearly stated by the reporter (e.g., day 0 or
day 1).
34) The duration of possible VTD should be analyzed as the interval between date/
time of onset5 or first observation6 or diagnosis7 and the end of episode8 or last
observation9. Whatever start and ending dates are used, they should be clearly
defined and used consistently within and across study groups and surveillance
systems. For any cases that are an exception to the standard used (e.g., because
of missing data), reports should note the reason(s) for the difference(s).
10To determine the appropriate category, the user should first establish whether a reported event meets the criteria for the lowest
applicable level of diagnostic certainty, i.e., Level 3. If the lowest applicable level of diagnostic certainty of a definition is met and
there is evidence that the criteria of the next higher level of diagnostic certainty are met, the event should be classified in the next
higher category. This approach should be continued until the highest level of diagnostic certainty for a given event has been
determined. If the lowest level of a case definition is not met, the user should confirm that none of the higher levels of diagnostic
certainty are met before finally classifying the event in category 4 or 5.
11If an adverse event (AE) reported as VTD does not meet Levels 1, 2, or 3 of the VTD case definition, then additional diagnostic
studies should be done to further search for diagnoses not previously considered that could explain the clinical picture of the AE.
12If the evidence available for an event is insufficient to permit classification by any level of diagnostic certainty (e.g., because of
missing information), such an event should be categorized as “Reported VTD with insufficient evidence to meet the case definition.”
Notations should be made as to what evidence is missing.
13If there is adequate evidence that an event does not meet the case definition, the event should be rejected and should be reported as
“Not a case of VTD.” Such evidence is considered adequate if the investigation reveals negative findings for all necessary criteria
(necessary conditions) for diagnosis. Such an event should be rejected and classified as “Not a case of VTD.”
14The YF vaccine causality classification scheme detailed in this document is different from the more general WHO scheme for
causality assessment of AEFI, currently undergoing revision and available at:
http://www.who.int/vaccines-documents/DocsPDF05/815.pdf.
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35) If more than one measurement of a particular parameter is taken and recorded,
the value corresponding to the largest deviation from the expected normal value
or range of that parameter should be used as the basis for analysis (e.g., highest
creatinine, lowest platelet count). Analysis may also include other characteristics
like qualitative patterns of criteria defining the event (e.g., periodicity,
frequency, etc.).
36) Given that VTD is a rare adverse event following immunization, the reported
values or time course should be presented individually as case reports.
37) Data on VTD cases should be compared with those obtained from one or more
appropriately selected and documented comparison group(s) and should be
analyzed by study arm and dose, as applicable.
38) Events should be coded as either unknown or missing under the following
circumstances: for missing events, no data were available through record
review; for unknown events, data were available but the reporter was uncertain
of the answer.
3.3. Data presentation
The following guidelines represent a desirable standard for presentation or publication of
analyzed AEFI data to allow comparability in vaccine safety. They are not guidelines for
primary reporting of AEFI to a study monitor. Additional information collected and
analyzed may be presented depending on the study question and setting. The WG
recommends that researchers also refer to other guidelines, including CONSORT
(Consolidated standards of reporting trials), QUORUM (Improving the quality of reports of
meta-analyses of randomized controlled trials), TREND (Transparent reporting of
evaluations with nonrandomized designs), STROBE (Strengthening the reporting of
observational studies in epidemiology), and MOOSE (Meta-analysis of observational studies
in epidemiology) for presentation and publication of randomized controlled trials, meta-
analyses, nonrandomized designs, observational studies, and systematic reviews of vaccine
safety studies, respectively [47–51].
39) Data on VTD should be presented in accordance with the data analysis
guidelines in Section 3.2.
40) Terms to describe VTD, such as “low-grade,” “mild,” “moderate,” “high,”
“severe,” or “significant,” are highly subjective, prone to wide interpretation,
and should be avoided unless validated or clearly defined.
41) Data should be presented with numerator and denominator (n/N) and not only in
percentages or graphical illustrations. The denominator should be clearly
defined (e.g., number of doses delivered for the campaign or lot number). These
data should be further analyzed by lot or vaccine, if applicable.
42) If the distribution of data is skewed, median and range are usually the more
appropriate statistical descriptors than a mean. However, the mean and standard
deviation, as well as the median and range, should also be provided to permit
meta-analysis.
43) The incidence15 of events meeting the case definition should be presented and
clearly identified as such in the text. The population for which the incidence is
15For example, 10 cases of VTD among 100,000 doses administered, or 2 cases of VTD on day 1, 3 cases on day 2, 10 cases on day 3
following immunization, or 10 cases after the first dose, 1 case after the second dose, 0 cases after the third dose.
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calculated and the source of these data should be clearly described (e.g., per
doses distributed or administered).
44) Any publication of VTD data should include as detailed as possible a description
of the methods used for data collection and analysis. It is essential to specify (as
applicable):
• The study design.
• The study group(s) including comparison group(s).
• The instrument of data collection (e.g., standardized questionnaire,
diary card).
• The method, frequency, and duration of monitoring for VTD.
• Whether the day of immunization was considered “day zero” or “day
one” in the analysis.
• Whether the date of onset5 and/or the date of first observation6 and/or
the date of diagnosis7 and the end of episode8 and/or last observation9
were used for analysis.
• The data analysis plan per protocol, and the statistical plan; and any
amendments to these sections of the protocol added during the study.
• The trial profile indicating participant flow during a study, including
drop-outs and withdrawals, to indicate the size and nature of the
respective groups under investigation; and
• Reference of the case definition used (Brighton or other) for VTD in
the abstract or methods section of a publication.16
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A.1. Further classification of a VTD case as an adverse event following
immunization with yellow fever vaccine
A.1.1. Causal association
Vaccine strain 17D YF virus can be detected in blood by virus culture or viral RNA
amplification using reverse transcriptase-polymerase chain reaction (RT-PCR). Viremia
with 17D YF virus occurs normally after primary YF vaccination, but not with booster doses
[52,53]. It has been demonstrated by plaque-forming assay that the normal viremia after
primary vaccination with17D YF virus occurs at 4–6 days postvaccination in most persons
and disappears by day 10 [53–55]. The peak viremia is less than 100 PFU/mL [52–54].
Although the detection of circulating 17D YF viral RNA by RT-PCR is more sensitive than
virus isolation [52], only limited data have been published characterizing the peak and time
course for circulating 17D YF viral RNA in normal vaccine recipients. Several studies have
detected 17D YF viral RNA by RT-PCR in the blood of healthy subjects at days 6–11 after
vaccination, although only in a small percentage of subjects at day 11 [52,56,57][CDC,
unpublished data, 2010]. Depending on the study, 17D YF viral RNA was undetectable by
day 11 or 14. These data on the kinetics of 17D YF virus in the blood of healthy vaccines
are instrumental in establishing the various levels of certainty for YF vaccine causality in the
algorithm below.
Tissue can be tested for the presence of 17D YF virus by using the techniques of virus
isolation, RT-PCR, and immunohistochemistry (IHC). With rare exceptions, human tissue
has been available only postmortem for testing in fatal cases of YEL-AVD, since biopsy is
contraindicated in severe YEL-AVD with coagulopathy because of the risk of significant
hemorrhage. A biodistribution study of healthy vaccinated monkeys detected the 17D YF
virus in the liver of one monkey and in the lymphoid tissue of several [58]. Consequently,
there is reason to believe that 17D YF virus might also be distributed in the tissues of
healthy human vaccines. However, no data exist regarding the normal kinetics and
distribution of 17D YF virus in human tissue following vaccination, which limits the degree
of certainty that can be assigned to positive YF test results of tissue in the causality
algorithm.
Characteristic histopathologic findings in the liver described in fatal cases of wild type YF
and YEL-AVD are Councilman bodies and midzonal necrosis. However, these findings are
not unique to these diseases [20]. A limitation of IHC is that it is usually performed with a
polyclonal antibody that reacts to both wild type YF and 17D YF virus. Because of their
lack of specificity for 17D YF virus, both IHC and histopathology test results need to be
interpreted in light of the patient’s potential to have been exposed to wild type YF virus
around the time of vaccination (i.e., travel to or residence in an area with known YF virus
circulation).
A.1.2. Case classification
This algorithm is based on the kinetics of 17D YF vaccine viremia in healthy vaccinees and
assumes a normal immune system. Individuals with immunosuppression or immune
dysregulation (inherited, acquired or medically induced) who are vaccinated with 17D YF
virus might have altered response with either higher or longer duration of viremia. Since
there are no data on the kinetics of viremia following YF vaccination in persons with altered
immune systems, these guidelines and criteria might not be as applicable for determining
vaccine causality of AEFI among such patients and should be used with caution.
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Testing for 17D YF vaccine virus should be performed by a laboratory that is proficient in
and has previously conducted YF testing, including the differentiation of vaccine from wild-
type virus strains; generally this will be a national or regional reference laboratory.
VTD — causality criteria for yellow fever vaccine14—To be classified as one of the
four categories of yellow fever vaccine-associated causality below, a reported case of VTD
should meet all the following criteria:
• The case is an adverse event following documented or confirmed YF vaccination
that either meets the VTD case definition (Level 1,2, or 3) or is classified as
reported VTD with insufficient evidence to meet the case definition
• Symptom onset is within 10 days of vaccination
• There is no laboratory evidence of another diagnosis
1. Definite yellow fever vaccine-associated causalityOne or more of the following are present:
• Yellow fever 17Da virus isolation from blood >10 days postvaccination
• Yellow fever 17Da virus concentration in blood ≥3 log10 pfu/mL on any day
• Yellow fever 17Da viral RNA amplification from blood ≥14 days post vaccination
• Isolation of yellow fever 17Da virus OR amplification of yellow fever 17Da viral RNA from tissue AND
histopathology consistent with yellow fever (e.g., liver midzonal necrosis, Councilman bodies)
• YF virus-specific antigen in tissue with characteristic vaccine-associated distribution (extrahepatic or
mesenchymal cell involvement) demonstrated by immunohistochemistry (IHC)b AND histopathology
consistent with yellow fever (e.g., liver midzonal necrosis, Councilman bodies) AND no history of being in
a yellow fever-endemic or -epidemic area within 10 days of symptom onset
2. Probable yellow fever vaccine-associated causalityOne or more of the following are present:
• Yellow fever 17Da virus isolation from blood 8–10 days post vaccination
• Yellow fever 17Da virus concentration in blood ≥2 log10 pfu/mL but < 3 log10 pfu/mL on any day 1–10
days postvaccination
• Yellow fever 17Da viral RNA amplification from blood ≥11 and <14 days postvaccination
• Isolation of yellow fever 17Da virus OR amplification of yellow fever 17Da viral RNA from tissuec
• Histopathology consistent with yellow fever (e.g., liver midzonal necrosis, Councilman bodies) AND no
history of being in a yellow fever-endemic or -epidemic area within 10 days of symptom onsetc
3. Suspect yellow fever vaccine-associated causalityOne or more of the following are present:
• Histopathology consistent with yellow fever (e.g., liver midzonal necrosis, Councilman bodies) AND
history of being in a yellow fever-endemic or -epidemic area within 10 days of symptom onset
• YF virus-specific antigen in tissue demonstrated by immunohistochemistry (IHC)b AND history of being in
a yellow fever-endemic or -epidemic area within 10 days of symptom onset
4. Insufficient data to determine yellow fever vaccine-associated causalityOne of the following:
• No yellow fever testing done
OR
• Yellow fever testing done and test results do not meet any of the criteria for causality Levels 1, 2, or 3
aboved
a
Confirmed as 17D virus by nucleotide sequencing.
b
Immunohistochemistry (IHC) performed by using polyclonal antibody to yellow fever viral antigen that reacts to both
17D yellow fever virus and wild type yellow fever virus.
c
If both the fourth and fifth criteria for probable YF vaccine-associated causality are present, this is equivalent to the
fourth criteria for definite YF vaccine-associated causality. In this case, the condition of “no history of recently being a in
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a YF-endemic/epidemic area within 10 days of symptom onset” is unnecessary, because the possibility of wild type YF
virus infection has been eliminated by the identification of 17D YF vaccine virus in tissue.
d
The presence or absence of serum YF virus-specific antibodies (IgM or IgG) has not been demonstrated to correlate with
or be predictive of YF vaccine causality in cases of VTD.
A.2. Other routes of transmission of yellow fever vaccine virus
Although direct vaccination is by far the predominant route of exposure to 17D YF vaccine
virus, breastfeeding and transfusion are other potential, albeit rare, routes of exposure. One
confirmed and two probable cases have been reported of breastfeeding-associated
transmission of 17D YF virus resulting in YF vaccine-associated neurologic disease
(encephalitis) in very young, exclusively breastfed infants [59–61]. However, the precise
mechanism of transmission (e.g., transmission through breast milk or direct blood-to-blood
transmission involving excoriated maternal nipple and infant oral mucosa) has not been
established. In addition, transfusion transmission of 17D YF virus to recipients of various
blood products donated by recently vaccinated persons has been confirmed serologically
[62]. No adverse events attributable to the 17D YF virus were identified in the recipients of
the blood products. To date, however, no data suggest that YEL-AVD has been associated
with any route of 17D YF virus exposure other than by direct vaccination.
Appendix B
B.1. Data collection checklist for viscerotropic disease (VTD)
This checklist serves as a template for data abstraction based on criteria listed in the case
definition and guidelines for data collection. It is intended to assist with data collection in
study protocols and active follow-up in surveillance systems. Additional information or a
different format may be required, depending on the study question and setting.
The Brighton VTD Working Group recommended that reports be collected from all persons
with symptoms consistent with VTD within 30 days of their vaccination.
A. Source of information/reporter
In accordance with country-specific data protection laws.
B. Vaccinee/Control details
In accordance with country-specific data protection laws.
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C. Details of the recent immunizations
For all immunizations given within 30 days prior to onset of VTD symptoms (if more
than 5 vaccines were given, please copy table and provide the information for each of the
vaccines)
Gershman et al. Page 24













Gershman et al. Page 25













D. The adverse event
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B.2. Data collection checklist for 17D yellow fever (YF) vaccine causality
assessment
For cases in which YF vaccine was administered and YF virus-specific testing performed
If YF virus-specific testing performed on tissue:
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